We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Role of Growth Factor Receptors in Neural Stem Cells Differentiation and Dopaminergic Neurons Generation

Lucía Calatrava, Rafael Gonzalo-Gobernado, Antonio S. Herranz, Diana Reimers, Maria J. Asensio, Cristina Miranda and Eulalia Bazán
Department of Neurobiology, Ramón y Cajal Institute for Health Research, Madrid Spain

1. Introduction

Neural stem cells (NSCs) are defined as clonogenic cells with self-renewal capacity and multilineage potential (Bazán et al., 2004). Cells with these characteristics have been isolated from the embryonic and adult Central Nervous System (CNS) (Gil-Perotin et al., 2009; Merkle & Alvarez-Buylla, 2006; Weiss et al., 1996). Under specific conditions, these cells proliferate in culture as cell clusters, called neurospheres, and differentiate into neurons, glia, and non-neural cell types (Kennea & Mehmet, 2002; Lobo et al., 2003; Reynolds & Weiss, 1992; Vescovi et al., 2002; Arias-Carrión & Yuan, 2009). Moreover, these cultures represent a potential source for cell replacement therapies in neurological diseases such as Parkinson's disease (PD) (Bjugstad et al., 2008; Pluchino et al., 2005; Reimers et al., 2011; Zhu et al., 2009).

Both basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) promote the proliferation of NSCs (Ciccolini & Svendsen, 1998; Gritti et al., 1996, 1999; Reynolds et al., 1992; Palmer et al., 1999). Moreover, growth factors (GFs) and intracellular mechanisms have been reported to influence or even determine NSCs phenotypic choice "in vivo" and "in vitro" (Daadi & Weiss, 1999; Hagg, 2005, 2009; Ninkovic & Götz, 2007; Redondo et al., 2007; Reimers et al., 2001, 2008). Thus, bFGF in combination with agents that increase cAMP levels and/or protein kinase C (PKC) activators induced the expression of tyrosine hydroxylase (TH), which is the rate-limiting enzyme involved in the synthesis of catecholaminergic neurotransmitters (Lopez-Toledano et al., 2004).

Growth factors exert their action through their interaction with specific receptors. A subset of FGF receptors (FGFRs) have been described in NSCs and their progeny (Reimers et al., 2001, Lobo et al., 2003), but to present nothing is known regarding the role played by these different FGFRs subtypes in the TH-inductive effect of bFGF above described. NSCs also express a 170 kD protein corresponding to the EGF receptor (EGFR) (Lobo et al., 2003). Since bFGF modulates EGF responsiveness in striatal precursors (Ciccolini & Svendsen, 1998), we wonderer whether TH induction in NSCs progeny could be associated with changes in EGFR protein expression and/or cellular localization.

2. Material and methods

2.1 Isolation of neural stem cells from the embryonic rat striatum

Striatal primordia from E15 Sprague-Dawley rat embryos were dissected and mechanically dissociated. Cells were grown in suspension in a defined medium (DF12) composed of Dulbecco's modified Eagle's medium and Ham's F-12 (1:1), 2 mM L-glutamine, 1 mM sodium pyruvate (all from Gibco BRL, Life Technologies Inc, Grand Island, NY), 0.6% glucose, 25 µg/ml insulin, 20 nM progesterone, 60 µM putrescine, and 30 nM sodium selenite (all from Sigma Chemical Co, St Louis, MO), 100 µg/ml human transferrin (Boehringer Mannheim GmbH, Germany) and 20 ng/ml human recombinant EGF (PreproTech EC Ltd., London, England). After 48-72 hr in vitro, the cells grew as free-floating neurospheres and were passaged by mechanical dissociation every 2-3 days (Lobo et al., 2003; Reimers et al., 2001).

After a minimum of 4 and a maximum of 5 passages, neurospheres were dissociated and plated at a density of 20,000–30,000 cells/cm² on 15 µg/ml poly L-ornithine (Sigma)-coated round glass cover slips (ø12 mm) or plastic dishes (ø 35 mm). Cultures were maintained in DF12 and 20 ng/ml EGF for 3 days and then switched to DF12 without EGF for longer culture periods (control group). At 7 days postplating (dpp), parallel cultures were treated with 10 ng/ml human recombinant bFGF (Boehringer Mannheim) and 1 mM dibutyryl adenosine 3,5-cyclic monophosphate (bFGF + dbcAMP) in the absence (vehicle group), or presence of 20 µM PD98058 or 10⁻⁷M staurosporin. Cellular phenotypes were determined immunocytochemically 24 hr later using antibodies to β-tubulin isotype III (β-tubulin III) for neurons, glial fibrillary acidic protein (GFAP) for astrocytes, A2B5, which stains bipotential O2A glial progenitors (Raff et al. 1984; Schnitzer & Schachner 1982) as well as subsets of neurons (Schnitzer & Schachner 1982), O4 for immature oligodendrocytes, O1 for mature oligodendrocytes, and TH for catecholaminergic phenotypes.

2.2 Immunocytochemical staining

The polyclonal antibodies used in this study were anti-β-tubulin III (BabCO; Richmond, CA), anti-TH (Chemicon International; Temecula, CA), anti-DOPA-decarboxylase (Sigma, Missouri, USA), anti-dopamine transporter (DAT, Chemicon), anti-vesicular monoamine transporter 2 (VMAT2, Pel-Freez, Arkansas LLC, USA) and anti-GFAP (Dako; Glostrup, Denmark). The antibodies used for the detection of FGF receptors (FGFR1, FGFR2, FGFR3), and EGF receptor (EGFR) were from Santa Cruz Biotechnology Inc., Burlingame, CA, USA. Monoclonal antibodies against β-tubulin III were obtained from Sigma, anti-TH was obtained from Chemicon, and anti-nestin (clone Rat 401) was from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IO). Monoclonal antibodies against A2B5, O4, and O1 were obtained in our laboratory as hybridoma supernatants. The secondary antibodies used were: biotinylated goat anti-mouse IgG (Zymed Laboratories; South San Francisco, CA), streptavidin-biotin-peroxidase complex (DakoCytomation), diaminobenzidine (DAB) + substrate-chromogen system (both from DakoCytomation), Alexa Fluor-568 goat anti-mouse IgG, Alexa Fluor-488 donkey anti-rat IgG, and Alexa Fluor-488 goat anti-rabbit IgG (1:400; all from Molecular Probes; Eugene, OR), Fluorescein-conjugated goat anti-mouse IgG (1:25; Jackson ImmunoResearch Laboratories Inc, West Grove, PA), Cy3-conjugated donkey anti-

guinea pig IgG (1:500, Jackson ImmunoResearch Laboratories Inc.), and Rhodamine-conjugated goat anti-rabbit IgG (1:100, Chemicon International Inc.).

For immunocytochemical studies, cells were fixed with 4% paraformaldehyde for 10 min and immunostained for A2B5 (1:10), O4 (1:10), O1 (1:10), FGFR1 (1:100), FGFR2 (1:100), FGFR3 (1:50) and EGFR (1:50) as previously described (Reimers et al., 2001). Permeabilization for GFAP (1:500), β -tubulin III (1:200 for monoclonal and 1:3000 for polyclonal anti- β -tubulin III, and TH (1:500) was achieved by treating cultures with 0.05% Triton X-100 at 4°C for 5min. Immunofluorescent procedures were applied for neural antigens and FGFR3 detection, and immunoperoxidase methods for FGFR1 and FGFR2 visualization. Cover slips were mounted in a medium containing p-phenylenediamine and bis-Benzimide (Hoechst 33342; Sigma).

2.3 Western blot protein analysis

NSCs progeny were treated for 24 hr with TH inducers, in the absence or presence of 20 μ M PD98058 or 10⁻⁷M staurosporin, and proteins were processed for Western blot analysis to determine the relative levels of growth factor receptors (GFRs) and neural antigens. Cells were lysed with 0.5 M Tris-HCl buffer (pH 7.4) containing 0.24% Triton X-100, 10 mg/ml leupeptin, and 0.5 mM PMSF, all from Sigma. After 1 hr at 4°C, samples were centrifuged at 12,000g for 30 min. Total protein content was quantified using a BCA kit (Pierce; Rockford, IL). Aliquots of 30 μ g of protein were separated by electrophoresis on 10% SDS-polyacrylamide minigels and transferred to nitrocellulose filters. Membranes were soaked in blocking solution (0.2 M Tris-HCl, 137 mM NaCl, and 3–5% dry skimmed milk, pH 7.6) and incubated with primary antibodies diluted in the same blocking solution: anti-FGFR1 (1:200), anti-FGFR3 (1:200), anti-EGFR (1:250), anti-TH (1:10,000), and anti-GFAP (1:1000), anti- β -tubulin III (1:10,000), and anti-CNPase (1:1000). After extensive washing membranes were incubated with the peroxidase-conjugated secondary antibodies diluted 1:1000 in blocking solution. The filters were developed with enhanced chemiluminescence Western blotting analysis, following the procedure described by the manufacturer (Amersham, Buckinghamshire, England). Membranes were immunolabeled for control charge using mouse anti- β actine (1:5000; Sigma Aldrich). Autoradiograms were quantified by computer-assisted videodensitometry.

2.4 Data analysis and cell counting

For Western blot analysis, results are expressed as mean $\pm$ SEM from two to four independent experiments. Where indicated, data represent the mean $\pm$ SEM of several cover slips. For each cover slip, stereological sampling of 25 visual fields (magnification of 200x or 400x) was performed by fluorescence microscopy. The number of cells was corrected for cover slip area. Statistical analyses were performed using Student's t-test or one-way ANOVA followed by Newman-Keuls multiple comparison test, and differences were considered significant at $p \leq 0.05$.

3. Results and discussion

3.1 Acquisition of a dopaminergic phenotype in the progeny of neural stem cells

Previously, we demonstrated that bFGF in combination with the PKA activator dbcAMP induced TH immunoreactivity in a subset of neurons and A2B5-positive progenitors

derived from striatal EGF-expanded NSCs (striatal EGF-NSCs) (Lopez-Toledano et al., 2004). However, to present nothing is known regarding the ability of bFGF + dbcAMP to promote the expression of other features of dopaminergic mature neurons in these cells. As shown in Fig. 1A, bFGF + dbcAMP treatment increased by 1.5-fold TH protein expression in the progeny derived from striatal EGF-NSCs.

Fig. 1. Induction of a dopaminergic phenotype in the progeny derived from striatal EGF-NSCs. As shown in A-C, bFGF + dbcAMP treatment (black bars) increased the expression of TH (A), VMAT2 (B) and DAT (C). Note how 20 μ M PD98059 (vertical line bars) and 10⁻⁷M staurosporin (horizontal line bars) prevented TH protein overexpression (A). Line 1, control cultures, line 2, bFGF + dbcAMP treated cultures, line 3, bFGF + dbcAMP in the presence of PD98059, line 4, bFGF + dbcAMP in the presence of staurosporin. Results represent the mean $\pm$ SEM of 2 independent experiments. ** $p \leq 0.01$ vs control. D shows how in bFGF + dbcAMP treated cultures DOPA-decarboxylase immunoreactivity (D, green) associates with TH-positive cells (D, red, white arrows).

In the presence of 20 μ M PD98059 or 10⁻⁷ M staurosporin, which are inhibitors of the mitogen activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK1/2) and PKC, respectively, the raise in TH protein levels promoted by bFGF + dbcAMP treatment was prevented (Fig. 1A). These results are in agreement with our previous studies showing that the activation of the MAPK/ERK1/2 signaling pathway and PKC activity were required for the generation of TH-positive cells in striatal EGF-NSCs progeny (Lopez-Toledano et al., 2004). Besides TH, bFGF + dbcAMP treated cultures also showed DOPA-decarboxylase immunoreactivity that in some cases was associated with TH-positive cells (Fig. 1D). This enzyme catalyzes the conversion of levodopa (L-DOPA) in dopamine, so we may consider that under TH-inductive conditions striatal EGF-NSCs progeny is able to

synthesize this neurotransmitter which deficit is involved in the progression of PD (Aron et al., 2011). As a matter of fact, our preliminary studies indicate that bFGF + dbcAMP treatment significantly increases L-DOPA levels by 1.7-fold ($p \leq 0.01$ vs control). Moreover, in the presence of the DOPA-decarboxylase inhibitor NSD-1015, L-DOPA levels were significantly higher than those observed under control conditions ($p \leq 0.001$), or bFGF + dbcAMP treatment ($p \leq 0.01$). Altogether, these results strongly suggest that under our experimental conditions TH and DOPA-decarboxylase are active enzymes.

We also analyzed the effect of the TH-inductive treatment in the expression of other dopaminergic markers such as VMAT2 and DAT. Thus, bFGF + dbcAMP increased by 2-fold VMAT2 and DAT protein levels (Fig. 1B, C). The expression of both proteins was not regulated by the MAPK/ERK1/2 signaling pathway or PKC activity because neither PD98059, nor staurosporin prevented VMAT2 or DAT upregulation (Fig. 1C, D). In our cultures, bFGF + dbcAMP treatment increased the phosphorylation of the cyclic AMP response element binding protein (CREB) probably through the activation of PKA by dbcAMP (Lopez-Toledano et al., 2004). Because this transcription factor regulates the expression of catecholamine biosynthetic enzymes and transporters (Lewis-Tuffin et al., 2004; Lim et al., 2000; Watson et al., 2001), its activation could be responsible for the increase in VMAT2 and DAT protein levels observed in this study. Besides, bFGF + dbcAMP could stimulate striatal EGF-NSCs to release neurotrophins that are able to increase the expression of TH and monoamine transporters in neural precursors (Maciaczyk et al., 2008; Sun et al., 2004), and in the damaged brain (Emborg et al., 2008).

3.2 Dopaminergic inducers modulate the expression and cellular localization of fibroblast growth factor receptors in the progeny of neural stem cells

Striatal EGF-NSCs and their progeny express a subset of FGFRs, so we were interested in to determine the role played by the different FGFR subtypes in the acquisition of dopaminergic features in these cells. FGFR1 is expressed in nestin-positive neural precursors (Lobo et al., 2003), and was down-regulated during their differentiation in neurons and glial cells (Reimers et al., 2001). Under dopaminergic-inductive conditions, FGFR1 immunoreactivity was higher than in controls (Fig. 2A, C). Similarly, FGFR1 protein expression was significantly raised by more than 10-fold in bFGF + dbcAMP treated cultures (Fig. 2B). FGFR1 up-regulation was not affected in the presence of MAPK/ERK1/2 or PKC inhibitors (Fig. 2B, D), indicating that other signaling pathways are involved in FGFR1 over-expression. Growth factors are able to stimulate the phosphatidylinositol 3-kinase (PI3K)/Akt signaling transduction pathway in NSCs to promote their proliferation, survival and differentiation (Lim et al., 2007; Meng et al., 2011; Nguyen et al., 2009; Torroglosa et al., 2007). As mentioned above, FGFR1 is expressed in nestin-positive neural precursors. In our cultures, bFGF + dbcAMP treatment significantly increased nestin protein expression by 2-fold ($p \leq 0.05$ vs control), and neither PD98059 nor staurosporin were able to abolish this effect. Because similar results were observed under bFGF treatment (Reimers et al., 2001), our results strongly suggest that the GF promotes the survival and/or proliferation of resting FGFR1-/nestin-positive neural precursors probably through the stimulation of PI3K/Akt signaling pathway.

Dopaminergic-inductive conditions modulate FGFR3 protein expression and cellular localization. Under control conditions, FGFR3 was localized in the membrane of GFAP-positive astrocytes (Fig. 3A), in the cell bodies of β -tubulin III-positive neurons (Fig. 3B), and in the nuclei of O4-positive preoligodendrocytes (Fig. 3C). Western blot analysis revealed

that FGFR3 levels were significantly up-regulated by bFGF + dbcAMP treatment (Fig. 3D). This experimental condition changed the morphology of GFAP-positive cells that showed longer and thinner processes where FGFR3 immunoreactivity was observed (Fig. 3E). Moreover, FGFR3 immunostaining was also detected in their nuclei (Fig. 3E). bFGF + dbcAMP treatment also affected to the morphology of O4-positive cells and increased FGFR3 immunoreactivity in their nuclei (Fig. 3G). Besides, some TH-positive cells showing a neuronal morphology co-expressed FGFR3 in their cell bodies (Fig. 3F). Other authors have shown the presence of two forms of FGFR3 in the nucleus of malignant and non-malignant epithelial cells (Johnston et al., 1995; Zammit et al., 2001). However, to our knowledge this is the first study reporting the nuclear localization of FGFR3 in neural cells. From our results, it is difficult to determine whether the higher levels of FGFR3 nuclear staining observed in GFAP-positive cells are due to the increase in protein expression, or to the translocation of FGFR3 to perinuclear localization.

Fig. 2. Tyrosine hydroxylase inducers upregulate FGFR1 protein expression in the progeny derived from striatal EGF-NSCs. A, C and D show FGFR1 immunocytochemical staining in control conditions (A), and in cultures treated with bFGF + dbcAMP (T) in the absence (C) or presence of 20 μ M PD98059 (D). Note how in the presence of TH-inducers FGFR1 immunoreactivity is increased (C). bFGF + dbcAMP treatment also upregulates FGFR1 protein expression (B, black bar), and this effect is not prevented by 20 μ M PD98059 (B, vertical lines bar) or 10⁻⁷M staurosporin (B, horizontal lines bar). Line 1, control cultures, line 2, bFGF + dbcAMP treated cultures, line 3, bFGF + dbcAMP in the presence of PD98059, line 4, bFGF + dbcAMP in the presence of staurosporin. Results represent the mean $\pm$ SEM of 2 independent experiments. **p $\leq$ 0.01 vs control.

Fig. 3. Tyrosine hydroxylase inducers modulate FGFR3 protein expression and cellular localization in the progeny derived from striatal EGF-NSCs. A-C show how under control conditions FGFR3 immunoreactivity (green) is localized in the membranes of GFAP-positive astrocytes (A, white arrows), cell bodies of β -tubulin III-positive neurons (B, yellow), and nuclei of O4-positive preoligodendrocytes (C). E-I show FGFR3 immunostaining in basic FGF + dbcAMP treated cultures (T). Under TH-inductive conditions, FGFR3 is localized in the nuclei of GFAP-positive astrocytes (E, white arrowheads) and preoligodendrocytes (G), and in the cell bodies of TH-positive neurons (F, yellow). Note, how astrocytes (E, red) and O4-positive cells (G, red) show longer and thinner extensions in bFGF + dbcAMP treated cultures, and how FGFR3 immunoreactivity is decreased in the presence of 20 μ M PD98059 (H, green) and 10⁻⁷M staurosporin (I, green). TH inducers also upregulate FGFR3 protein expression (D, black bar), and this effect is prevented by 20 μ M PD98059 (D, vertical lines bar) or 10⁻⁷M staurosporin (D, horizontal lines bar). Line 1, control cultures, line 2, bFGF + dbcAMP treated cultures, line 3, bFGF + dbcAMP in the presence of PD98059, line 4, bFGF + dbcAMP in the presence of staurosporin. Results represent the mean $\pm$ SEM of 4 independent experiments. * $p \leq 0.05$ vs control, $^+p \leq 0.05$ vs vehicle.

Interestingly, the nuclear translocation of FGFRs in response to bFGF has been reported in reactive astrocytes (Clarke et al., 2001) and Swiss 3T3 fibroblasts (Maher, 1996). Moreover, the antibody used in this study recognizes a 135 kDa form of FGFR3 that showed a mix of nuclear and cytoplasmic localization in epithelial cells that depends on its degree of activation by different members of the FGF family (Zammit et al., 2001).

Similarly to TH protein expression, FGFR3 up-regulation was not observed in the presence of 20 μ M PD98059 or 10⁻⁷M staurosporin (Fig. 3D). FGFR3 immunoreactivity was also reduced in both experimental conditions (Fig. 3H, I). Moreover, PKC inhibition prevented the morphological changes promoted by bFGF + dbcAMP treatment (Fig. 3I). These results suggest that the modulation of FGFR3 and TH induction are two events closely associated. As a matter of fact, FGFRs nuclear localization has been related with the differentiation of neural progenitor cells (Fang et al., 2005; Stachowiak et al., 2003), and TH gene expression

(Peng et al., 2002). We should comment that not all TH-positive cells were FGFR3 immunoreactive (our unpublished observations), so it seems that they are not direct targets for bFGF. Under our TH-inductive conditions, GFAP protein expression was significantly raised by more than 1.6-fold ($p \leq 0.05$ vs control). GFAP over-expression and morphological changes are features of reactive glia which is able to synthesize trophic factors involved in neuronal survival and differentiation (Barreto et al., 2011). Because glial derived factors are also involved in the differentiation of NSCs in TH-immunoreactive dopaminergic neurons (Anwar et al., 2008; Maciaczyk et al., 2008; Sun et al., 2004), from our results we propose that stimulation of FGFR3 localized in glial cells mediate the release of several unknown factors that in combination with PKA activators stimulate TH-induction in the target cells. In fact, glial conditioned medium in combination with PKA activators elicits the expression of TH in the progeny of striatal EGF-NSCs (Reimers et al., 2008).

We have also analyzed the effects of bFGF + dbcAMP treatment in FGFR2 expression. Under the experimental conditions presented in this study, FGFR2 nuclear localization and FGFR2 protein expression were not affected (data not shown), indicating that probably this FGFR is not involved in the acquisition of a dopaminergic phenotype in striatal EGF-NSCs progeny.

3.3 Tyrosine hydroxylase-inducing cues trigger nuclear epidermal growth factor receptor accumulation in the progeny of neural stem cells

EGFR stimulation is essential for the proliferation of striatal EGF-NSCs (Bazán et al., 1998, 2006; Reimers et al., 2001). EGFR protein expression has been detected during the differentiation of these cells in neurons and glia (Lobo et al., 2003); however, to present nothing is known regarding its cellular localization, and the role, if any, played by this receptor in the differentiation of striatal EGF-NSCs to TH-immunopositive cells. As shown in Fig. 4A, EGFR-positive cells were observed in 8 dpp control cultures. At this experimental time, EGFR immunoreactivity was localized in the cell bodies of β -tubulin III- (Fig. 4B) and O4-positive cells (Fig. 4D). Moreover, EGFR immunostaining was also observed in the membrane of GFAP-positive astrocytes (Fig. 4C). TH-inductive conditions did not affect EGFR protein expression (Fig. 4K), but promoted the translocation of EGFR to the nuclei in many cells (Fig. 4E). Nuclear EGFR immunoreactivity was observed in small spots, suggesting that the EGFR could be localized in the nucleolar compartment. Functional nuclear EGFR have been described in normal and tumoral cells (Jaganathan et al., 2011; Lo & Hung, 2007; Xu et al., 2009), but to our knowledge this is the first study reporting the nuclear localization of EGFR in NSCs and its derived progeny. Interestingly, a recent report discusses the possibility that proliferation and differentiation of NSCs could be controlled by nuclear receptors (Katayama et al., 2005). Moreover, NSCs proliferation seems to be regulated by a nucleolar mechanism that involves the interaction of proteins located in their nucleoli (Tsai & McKay, 2002). Neither EGFR protein expression (Fig. 4K), nor nuclear localization (Fig. 4I) were affected in the presence of PD98059. However, both parameters were significantly reduced in the presence of the PKC inhibitor staurosporin (Fig. 4J, K). As a matter of fact, a recent report demonstrates that PKC activation triggers nuclear EGFR accumulation in a bronchial carcinoma cell line (Wanner et al., 2008). Besides, the nuclear translocalization of EGFR may require its phosphorylation at Ser-229 by Akt (Huang et al., 2011). Further experiments are warranted to determine whether the PI3K/Akt signaling pathway mediates bFGF + dbcAMP-induced EGFR nuclear translocalization in striatal EGF-NSCs.

Fig. 4. Tyrosine hydroxylase inducers elicit nuclear translocation of EGFR in the progeny derived from striatal EGF-NSCs. In control cultures EGFR immunoreactivity is localized the cell bodies (A, red), and in membranes (A, white arrows). Under this condition, EGFR is expressed in the cell bodies of neurons (B, yellow) and O1-positive oligodendrocytes (D), and in the membranes of GFAP-positive astrocytes (C, open triangle). Note how bFGF + dbcAMP (T) translocates EGFR to the nuclear compartment (E, white arrowheads), and how nuclear EGFR is observed in a few β -tubulin III-positive neurons (F, white star), a few astrocytes (G, open arrow), and in many A2B5-positive progenitors (H). Neither EGFR immunoreactivity nor nuclear EGFR localization are affected in the presence of 20 μ M PD98059 (I, red), but 10⁻⁷ M staurosporine significantly decreases both parameters (J, red). bFGF + dbcAMP treatment in the absence (K, black bar) or presence of 20 μ M PD98059 (K, vertical lines bar) does not affect EGFR protein expression; however, 10⁻⁷ M staurosporin significantly reduces EGFR levels (K, horizontal lines bar). Line 1, control cultures, line 2, bFGF + dbcAMP treated cultures, line 3, bFGF + dbcAMP in the presence of PD98059, line 4, bFGF + dbcAMP in the presence of staurosporin. Results represent the mean $\pm$ SEM of 2 independent experiments. +p $\leq$ 0.05 vs vehicle.

Double immunostaining showed that some neurons (Fig. 4F) and a few GFAP-positive astrocytes (Fig. 4G) presented nuclear EGFR immunoreactivity. Besides, a population of cells showing EGFR nuclear localization colabeled with A2B5-positive cells (Fig. 4H). Emerging evidence suggest that EGFR nuclear translocation regulates gene expression and mediate other cellular processes such as DNA repair (Chen & Nirodi, 2007; Dittmann et al., 2010; Lo, 2010). Its transcriptional activity depends on its C-terminal transactivation domain, and its physical and functional interaction with other transcription factors that lead the activation of genes (Lo & Hung, 2006). Under our experimental conditions TH is expressed in 4% of the total population of β -tubulin III-positive neurons, and 20% of the TH-positive cells colabel with A2B5 (Lopez-Toledano et al., 2004), so we may hypothesize that nuclear EGFR could regulate TH gene expression in both cell types.

Fig. 5. Schematic diagram illustrating how bFGF + dbcAMP treatment induces the expression of specific features of dopaminergic neurons in the progeny derived from striatal EGF-NSCs through the modulation of GFRs expression and cellular localization.

4. Conclusions

1. In striatal EGF-NSCs, bFGF + dbcAMP treatment up-regulates the expression of the specific dopaminergic markers TH, DAT and VMAT2.
2. FGFR1 and nestin protein levels are significantly raised in bFGF + dbcAMP treated cultures, suggesting the survival and/or proliferation of undifferentiated neural precursors under this experimental condition.

3. bFGF + dbcAMP treatment increases FGFR3 protein expression and FGFR3 immunoreactivity in the glial progeny derived from striatal-EGF-NSCs. Moreover, this experimental condition up-regulates GFAP protein levels, and elicits the translocation of FGFR3 to the nucleus in reactive GFAP-positive astrocytes.
4. In the presence of MAPK/ERK1/2 or PKC inhibitors, TH protein expression, FGFR3 up-regulation, and glial reactivity are partially prevented, suggesting that in bFGF + dbcAMP treated cultures, the modulation of FGFR3 in glial cells and TH induction are two events closely associated.
5. Under bFGF + dbcAMP treatment, EGFR immunostaining shows a nuclear localization in β -tubulin III-positive neurons and in A2B5-positive precursors derived from striatal EGF-NSCs. Because both cell types are able to express TH, we hypothesize that the nuclear translocation of EGFR is necessary for the induction of TH in these cells.

As summarize in Fig. 5, our results demonstrate that in striatal EGF-NSCs, bFGF and dbcAMP treatment induces TH protein expression through the stimulation of FGFR3 expressed in glia, and nuclear translocation of EGFR in the target cells. Under these TH-inductive conditions, striatal EGF-NSCs progeny acquire other specific features of mature dopaminergic neurons, so they can be considered as an excellent tool for stem cell-based replacement therapies in PD.

5. Acknowledgment

The authors wish to acknowledge the editorial for its invitation to contribute with a full chapter for the book under the working title "Neural Stem Cells", ISBN 978-953-307-795-6. This work was supported by the Fondo de Investigaciones Sanitarias (FISS PI060315) and Agencia Laín Entralgo (NDG7/09). RG-G and CM were the recipients of a FiBio HRyC fellowship, and LC was the recipient of an Agencia Laín Entralgo fellowship. We thank Macarena Rodríguez for technical help, and Dr. Maria José Casarejos for the determination of L-DOPA levels by HPLC.

6. References

- Anwar MR, Andreasen CM, Lippert SK, Zimmer J, Martinez-Serrano A & Meyer M (2008). Dopaminergic differentiation of human neural stem cells mediated by co-cultured rat striatal brain slices. *J Neurochem.*, Vol. 105, No. 2, (April 2008), pp.(460-70), ISSN 0022-3042.
- Arias-Carrión O & Yuan TF (2009). Autologous neural stem cell transplantation: A new treatment option for Parkinson's disease? *Med Hypotheses.*, Vol. 73, No. 5, (November 2009), pp. (757-759), ISSN 0306-9877.
- Aron L & Klein R (2011). Repairing the parkinsonian brain with neurotrophic factors. *Trends Neurosci.*, Vol. 34, No. 2, (February 2011), pp. (88-100), ISSN 0166-2236.
- Barreto GE, Gonzalez J, Torres Y & Morales L (2011). Astrocytic-neuronal crosstalk: Implications for neuroprotection from brain injury. *Neurosci Res.*, (June 2011) [Epub ahead of print]
- Bazán E, López-Toledano MA, Redondo C, Alcázar A, Paíno CL & Herranz AS. (1998). Characterization of rat neural stem cells from embryonic striatum and mesencephalon during in vitro differentiation. In: *Understanding glial cells*,

- Castellano B, González B, Nieto-Sampedro M, editors, pp. 133–147. Kluwer Academic Publishers, ISBN 0-7923-8140-8, Dordrecht, The Netherlands.
- Bazán E, Alonso FJ, Redondo C, López-Toledano MA, Alfaro JM, Reimers D, Herranz AS, Paíno CL, Serrano AB, Cobacho N, Caso E & Lobo MV (2004). In vitro and in vivo characterization of neural stem cells. *Histol Histopathol*, Vol. 19, No. 4, (October 2004), pp. (1261-75), ISSN 0213-3911.
- Bazán E, Herranz AS, Reimers D, Lobo MVT, Redondo C, López-Toledano MA, Gonzalo-Gobernado R, Asensio MJ & Alonso R. (2006). Neural stem cells and taurine. In: *Neural stem cell research*, Greer EV, editor, pp 99–114. Nova Science Publishers, Inc, ISBN 1-59454-846-3, New York.
- Bjugstad KB, Teng YD, Redmond DE Jr, Elsworth JD, Roth RH, Cornelius SK, Snyder EY & Sladek JR Jr (2008). Human neural stem cells migrate along the nigrostriatal pathway in a primate model of Parkinson's disease. *Exp Neurol.*, Vol. 211, No. 2, (June 2008), pp. (362-369), ISSN 0014-4886.
- Chen DJ & Nirodi CS (2007). The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. *Clin Cancer Res.*, Vol. 13, No. 22 Pt 1, (November 2007), pp. (6555-6560), ISSN 0008-5472.
- Ciccolini F & Svendsen CN (1998). Fibroblast growth factor 2 (FGF-2) promotes acquisition of epidermal growth factor (EGF) responsiveness in mouse striatal precursor cells: Identification of neural precursors responding to both EGF and FGF-2. *J Neurosci.*, Vol. 18, No. 19, (October 1998), pp. (7869–7880), ISSN 0270-6474.
- Clarke WE, Berry M, Smith C, Kent A & Logan A (2001). Coordination of fibroblast growth factor receptor 1 (FGFR1) and fibroblast growth factor-2 (FGF-2) trafficking to nuclei of reactive astrocytes around cerebral lesions in adult rats. *Mol Cell Neurosci*, Vol 17, No. 1, (January 2001), pp. (17-30), ISSN 1044-7431.
- Daadi MM & Weiss S (1999). Generation of tyrosine hydroxylase-producing neurons from precursors of the embryonic and adult forebrain. *J Neurosci.*, Vol. 19, No. 11, (June 1999), pp. (4484-97), ISSN 0270-6474.
- Dittmann K, Mayer C & Rodemann HP (2010). Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function. *Strahlenther Onkol.*, Vol. 186, No.1, (January 2010), pp.(1-6), ISSN 0179-7158.
- Emborg ME, Ebert AD, Moirano J, Peng S, Suzuki M, Capowski E, Joers V, Roitberg BZ, Aebischer P & Svendsen CN (2008). GDNF-secreting human neural progenitor cells increase tyrosine hydroxylase and VMAT2 expression in MPTP-treated cynomolgus monkeys. *Cell Transplant.* Vol. 17, No. 4, pp, (383-95), E-ISSN 1555-3892.
- Fang X, Stachowiak EK, Dunham-Ems SM, Klejbor I & Stachowiak MK (2005). Control of CREB-binding protein signaling by nuclear fibroblast growth factor receptor-1: a novel mechanism of gene regulation. *J Biol Chem.*, Vol. 280, No. 31, (August 2005), pp. (28451-28462), ISSN 0021-9258.
- Gil-Perotín S, Alvarez-Buylla A & García-Verdugo JM (2009). Identification and characterization of neural progenitor cells in the adult mammalian brain. *Adv Anat Embryol Cell Biol.*, Vol. 203, pp.(1-101), ISSN 0301-5556.
- Gritti A, Parati EA, Cova L, , Frölichsthal-Schoeller P, Galli R, Wanke E, Faravelli L, Morassutti DJ, Roisen F, Nickel DD & Vescovi AL (1996). Multipotent stem cells from the adult mouse brain proliferate and self-renewing response to basic

- .broblast growth factor. *J Neurosci.*, Vol. 16, No. 3, (February 1996), pp.(1091-1100), ISSN 0270-6474.
- Gritti A, Frölichsthal-Schoeller P, Galli R, Paraati EA, Cova L, Pagano SF, Bjornson CR & Vescovi AL (1999). Epidermal and fibroblast growth factors behave as mitogenic regulators for a single multipotent stem cell-like population from the subventricular region of the adult mouse forebrain. *J Neurosci.*, Vol. 19, No. 9,(May 1999), pp. (3287-3297), ISSN 0270-6474.
- Hagg T (2005). Molecular regulation of adult CNS neurogenesis: an integrated view. *Trends Neurosci.*, Vol. 28, No. 11, (November 2005), pp.(589-595), ISSN 0166-2236.
- Hagg T (2009). From neurotransmitters to neurotrophic factors to neurogenesis. *Neuroscientist.*, Vol. 15, No. 1, (February 2009), pp.(20-27), ISSN 1073-8584.
- Huang WC, Chen YJ, Li LY, Wei YL, Hsu SC, Tsai SL, Chiu PC, Huang WP, Wang YN, Chen CH, Chang WC, Chang WC, Chen AJ, Tsai CH & Hung MC (2011). Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. *J Biol Chem*, Vol. 286, No. 23, (June 2011), pp. (20558-68), ISSN 0021-9258.
- Jaganathan S, Yue P, Paladino DC, Bogdanovic J, Huo Q & Turkson J (2011). A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. *PLoS One.*, Vol. 6, No. 5, (May 2011), e19605, ISSN 1932-6203.
- Johnston CL, Cox HC, Gomm JJ & Coombes RC (1995). Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus. *J Biol Chem*, Vol. 270, No. 51 (December 1995), pp. (30643-50), ISSN 0021-9258.
- Katayama K, Wada K, Nakajima A, Kamisaki Y & Mayumi T (2005).Nuclear receptors as targets for drug development: the role of nuclear receptors during neural stem cell proliferation and differentiation. *J Pharmacol Sci*, Vol. 97, No. 2, (February 2005), pp. (171-6), ISSN 1347-8613.
- Kennea NL & Mehmet H (2002). Neural stem cells. *J Pathol.*, Vol. 197 , No. 4, (July 2002), pp. (536-550), ISSN 1096-9896.
- Lewis-Tuffin LJ, Quinn PG & Chikaraishi DM (2004). Tyrosine hydroxylase transcription depends primarily on cAMP response element activity, regardless of the type of inducing stimulus. *Mol Cell Neurosci.*,Vol. 25, No. 3, (March 2004), pp. (536-547), ISSN 1044-7431.
- Lim J, Yang C, Hong SJ & Kim KS (2000). Regulation of tyrosine hydroxylase gene transcription by the cAMP-signaling pathway: involvement of multiple transcription factors. *Mol Cell Biochem* , Vol. 212, No. 1-2, (September 2000), pp. (51-60), ISSN 0300-8177.
- Lim MS, Nam SH, Kim SJ, Kang SY, Lee YS & Kang KS (2007). Signaling pathways of the early differentiation of neural stem cells by neurotrophin-3. *Biochem Biophys Res Commun.*, Vol. 357, No. 4, (June 2007), pp. (903-909), ISSN 0006-291X.
- Lo HW & Hung MC (2006). Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. *Br J Cancer*, Vol. 94, No. 2, (January 2011), pp. (184-8), ISSN 0007-0920

- Lo HW & Hung MC (2007). Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. *Br J Cancer*, Vol. 96 Suppl, pp. (16-20), ISSN 0007-0920.
- Lo HW (2010). Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications. *Discov Med.*, Vol 10, No 50, (July 2010), pp. (44-51), ISSN 1539-6509.
- Lobo MV, Alonso FJ, Redondo C, López-Toledano MA, Caso E, Herranz AS, Paíno CL, Reimers D & Bazán E (2003). Cellular characterization of epidermal growth factor-expanded free-floating neurospheres. *J Histochem Cytochem*, Vol. 51, No. 1, (January 2003), pp. (89-103), ISSN 0022-1554.
- López-Toledano MA, Redondo C, Lobo MV, Reimers D, Herranz AS, Paíno CL & Bazán E (2004). Tyrosine hydroxylase induction by basic fibroblast growth factor and cyclic AMP analogs in striatal neural stem cells: role of ERK1/ERK2 mitogen-activated protein kinase and protein kinase C. *J Histochem Cytochem.*, Vol. 52, No. 9, (September 2004), pp. (1177-1189), ISSN 0022-1554.
- Maciaczyk J, Singec I, Maciaczyk D & Nikkhah G (2008). Combined use of BDNF, ascorbic acid, low oxygen, and prolonged differentiation time generates tyrosine hydroxylase-expressing neurons after long-term in vitro expansion of human fetal midbrain precursor cells. *Exp Neurol.*, Vol. 213, No. 2, (October 2008), pp. (354-362), ISSN 0014-4886.
- Maher PA (1996). Nuclear Translocation of fibroblast growth factor (FGF) receptors in response to FGF-2. *J Cell Biol*, Vol. 134, No. 2, (July 1996), pp. (529-36), ISSN 0021-9525.
- Meng X, Arocena M, Penninger J, Gage FH, Zhao M & Song B (2011). PI3K mediated electrotaxis of embryonic and adult neural progenitor cells in the presence of growth factors. *Exp Neurol.*, Vol. 227, No. 1, (January 2011), pp. (210-217), ISSN 0014-4886.
- Merkle FT & Alvarez-Buylla A (2006). Neural stem cells in mammalian development. *Curr Opin Cell Biol.*, Vol 18, No. 6, (December 2006), pp. (704-709), ISSN 0955-0674.
- Nguyen N, Lee SB, Lee YS, Lee KH & Ahn JY (2009). Neuroprotection by NGF and BDNF against neurotoxin-exerted apoptotic death in neural stem cells are mediated through Trk receptors, activating PI3-kinase and MAPK pathways. *Neurochem Res.*, Vol. 34, No. 5, (May 2009), pp. (942-951), ISSN 1573-6903.
- Ninkovic J & Gotz M (2007). Signaling in adult neurogenesis: from stem cell niche to neuronal networks. *Curr Opin Neurobiol.*, Vol. 17, No. 3, (June 2007), pp. (338-344), ISSN 0959-4388.
- Palmer TD, Markakis EA, Willhoite AR, Safar F & Gage FH (1999). Fibroblast growth factor-2 activates a latent neurogenic program in neural stem cells from diverse regions of the adult CNS. *J Neurosci.*, 19, No. 19, (October 1999), pp. (8487-8497), ISSN 0270-6474.
- Peng H, Moffett J, Myers J, Fang X, Stachowiak EK, Maher P, Kratz E, Hines J, Fluharty SJ, Mizukoshi E, Bloom DC & Stachowiak MK (2001). Novel nuclear signaling pathway mediates activation of fibroblast growth factor-2 gene by type 1 and type 2 angiotensin II receptors. *Mol Biol Cell.*, Vol. 12, No. 2, (February 2001), pp. (449-462), ISSN 1059-1524.

- Pluchino S, Zanotti L, Deleidi M & Martino G (2005). Neural stem cells and their use as therapeutic tool in neurological disorders. *Brain Res Brain Res Rev.*, Vol. 48, No. 2, (April 2005), pp. 211-219, ISSN 0165-0173.
- Raff MC, Abney ER, Miller RH (1984) Two glial cell lineages diverge prenatally in rat optic nerve. *Dev Biol.*, Vol. 106, No. 1, (November 1984), pp.(53-60), ISSN 0012-1606.
- Redondo C, López-Toledano MA, Lobo MV, Gonzalo-Gobernado R, Reimers D, Herranz AS, Paíno CL & Bazán E (2007). Kainic acid triggers oligodendrocyte precursor cell proliferation and neuronal differentiation from striatal neural stem cells. *J Neurosci Res.*, Vol. 85, No. 6, (May 2007), pp. (1170-1182), ISSN 0360-4012.
- Reimers D, López-Toledano MA, Mason I, Cuevas P, Redondo C, Herranz AS, Lobo MV & Bazán E (2001). Developmental expression of fibroblast growth factor (FGF) receptors in neural stem cell progeny. Modulation of neuronal and glial lineages by basic FGF treatment. *Neurol Res.*, Vol. 23, No. 6, (September 2001), pp. (612-621), ISSN 0161-6412.
- Reimers D, Gonzalo-Gobernado R, Herranz AS, Osuna C, Asensio MJ, Baena S, Rodríguez M & Bazán E (2008). Driving neural stem cells towards a desired phenotype. *Curr Stem Cell Res Ther.*, Vol. 3, No. 4, (December 2008), pp.(247-253), ISSN 1574-888X.
- Reimers D, Osuna C, Gonzalo-Gobernado R, Herranz AS, Díaz-Gil JJ, Jiménez-Escrig A, Asensio MJ, Miranda C, Rodríguez-Serrano M & Bazán E (2010). Liver Growth Factor Promotes the Survival of Grafted Neural Stem Cells in a Rat Model of Parkinson's Disease. *Curr Stem Cell Res Ther.*, (December 2010), [Epub ahead of print], ISSN 1574-888X.
- Reynolds BA & Weiss S (1992). Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. *Science.*, Vol. 255, No. 5052, (March 1992), pp. (1707-1710), ISSN 0036-8075.
- Reynolds BA, Tetzlaff W & Weiss S (1992). A multipotent EGF responsive striatal embryonic progenitor cell produces neurons and astrocytes. *J Neurosci.*, Vol. 12, No. 11, (November 1992), pp. (4565-4574), ISSN 0270-6474.
- Schnitzer J & Schachner M (1982) Cell type specificity of a neural cell surface antigen recognized by the monoclonal antibody A2B5. *Cell Tissue Res.*, Vol. 224, No. 3, pp. (625-636), ISSN 0302-766X.
- Stachowiak EK, Fang X, Myers J, Dunham S & Stachowiak MK (2003). cAMP-induced differentiation of human neuronal progenitor cells is mediated by nuclear fibroblast growth factor receptor-1 (FGFR1). *J Neurochem.*, Vol. 84, No. 6, (March 2003), pp. (1296-1312), ISSN 0022-3042.
- Sun ZH, Lai YL, Li P, Zuo HC & Xie ZP (2004). GDNF augments survival and differentiation of TH-positive neurons in neural progenitor cells. *Cell Biol Int.*, Vol. 28, No. 4, pp. (323-325), ISSN 1065-6995.
- Torroglosa A, Murillo-Carretero M, Romero-Grimaldi C, Matarredona ER, Campos-Caro A & Estrada C (2007). Nitric oxide decreases subventricular zone stem cell proliferation by inhibition of epidermal growth factor receptor and phosphoinositide-3-kinase/Akt pathway. *Stem Cells* Vol. 25, No. 1, (January 2007), pp. (88-97), ISSN 1066-5099.
- Tsai RY & McKay RD (2002). A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. *Genes Dev.*, Vol. 16, No. 23, (December 2002), pp. (2991-3003), ISSN 0890-9369.

- Vescovi AL, Rietze R, Magli MC, Bjornson C (2002). Hematopoietic potential of neural stem cells. *Nat Med.*, Vol. 8, No. 6, (June 2002), pp. (535; author reply 536-537), ISSN 1078-8956.
- Wanner G, Mayer C, Kehlbach R, Rodemann HP & Dittmann K (2008). Activation of protein kinase Cepsilon stimulates DNA-repair via epidermal growth factor receptor nuclear accumulation. *Radiother Oncol.*, Vol. 86, No. 3, (March 2008), pp. (383-390), ISSN 0167-8140.
- Watson F, Kiernan RS, Deavall DG, Varro A & Dimaline R (2001). Transcriptional activation of the rat vesicular monoamine transporter 2 promoter in gastric epithelial cells: regulation by gastrin. *J Biol Chem.*, Vol. 276, No. 10, (March 2001), pp. (7661-7671), ISSN 0021-9258.
- Weiss S, Reynolds BA, Vescovi AL, Morshead C, Craig CG & van der Kooy D (1996). Is there a neural stem cell in the mammalian forebrain? *Trends Neurosci.*, Vol. 19, No. 9, (September 1996), pp. (387-393), ISSN 0166-2236.
- Xu Y, Shao Y, Zhou J, Voorhees JJ & Fisher GJ (2009). Ultraviolet irradiation-induces epidermal growth factor receptor (EGFR) nuclear translocation in human keratinocytes. *J Cell Biochem.*, Vol. 107, No. 5, (August 2009), pp. (873-880), ISSN 0730-2312.
- Zammit C, Barnard R, Gomm J, Coope R, Shousha S, Coombes C & Johnston C (2001). Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer. *J Pathol*, Vol. 194, No. 1, (May 2001), pp (27-34), ISSN 1096-9896.
- Zhu Q, Ma J, Yu L & Yuan C (2009). Grafted neural stem cells migrate to substantia nigra and improve behavior in Parkinsonian rats. *Neurosci Lett.*, Vol. 462, No. 3, (October 2009), pp. (213-218), ISSN 0304-3940.

IntechOpen

Neural Stem Cells and Therapy

Edited by Dr. Tao Sun

ISBN 978-953-307-958-5

Hard cover, 440 pages

Publisher InTech

Published online 15, February, 2012

Published in print edition February, 2012

This book is a collective work of international experts in the neural stem cell field. The book incorporates the characterization of embryonic and adult neural stem cells in both invertebrates and vertebrates. It highlights the history and the most advanced discoveries in neural stem cells, and summarizes the mechanisms of neural stem cell development. In particular, this book provides strategies and discusses the challenges of utilizing neural stem cells for therapy of neurological disorders and brain and spinal cord injuries. It is suitable for general readers, students, doctors and researchers who are interested in understanding the principles of and new discoveries in neural stem cells and therapy.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Lucía Calatrava, Rafael Gonzalo-Gobernado, Antonio S. Herranz, Diana Reimers, Maria J. Asensio, Cristina Miranda and Eulalia Bazán (2012). Role of Growth Factor Receptors in Neural Stem Cells Differentiation and Dopaminergic Neurons Generation, Neural Stem Cells and Therapy, Dr. Tao Sun (Ed.), ISBN: 978-953-307-958-5, InTech, Available from: <http://www.intechopen.com/books/neural-stem-cells-and-therapy/role-of-growth-factor-receptors-in-neural-stem-cells-differentiation-and-dopaminergic-neurons-genera>

INTech
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen